<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03105336</url>
  </required_header>
  <id_info>
    <org_study_id>KTE-C19-105</org_study_id>
    <secondary_id>2017-001912-13</secondary_id>
    <nct_id>NCT03105336</nct_id>
  </id_info>
  <brief_title>A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma</brief_title>
  <acronym>ZUMA-5</acronym>
  <official_title>A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite, A Gilead Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll approximately 160 adult subjects who have relapsed or refractory (r/r)
      iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease
      responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is
      made from the subjects own white blood cells which are genetically modified and grown to
      fight cancer. An objective response rate of 70% is targeted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll approximately 160 adult subjects who have relapsed or refractory (r/r)
      iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease
      responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is
      made from the subjects own white blood cells which are genetically modified and grown to
      fight cancer. An objective response rate of 70% is targeted.

      All enrolled subjects will be screened for eligibility then will undergo leukapheresis to
      collect white blood cells for manufacturing. In preparation for the infusion with
      axicabtagene ciloleucel, subjects will undergo conditioning chemotherapy with
      cyclophosphamide and fludarabine for 3 days to help the study treatment be effective. After
      the product is manufactured and conditioning chemotherapy period is complete, subjects will
      be infused with axicabtagene ciloleucel and then monitored in a hospital for a minimum of 7
      days. Subjects will be followed by their study doctor for continued monitoring of the safety
      and effectiveness of the study treatment for approximately 3 months after receiving treatment
      and then will be followed for safety for up to an additional 15 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Anticipated">February 2037</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate per central read</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Complete response (CR) + partial response (PR) per the Lugano Classiciation (Cheson et al, 2014).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR Rate per central read</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>CRR is defined as the incidence of CR as best response to treatment by the Lugano Classification (Cheson et al, 2014)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>DOR is defined only for subjects who experience an objective response and is the time from the first objective response to disease progression per (Cheson et al, 2014) or disease-related death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per (Cheson et al, 2014) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>OS is defined as the time from KTE-C19 infusion to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of anti-CD19 CAR T cells in blood</measure>
    <time_frame>At enrollment, Day 7, Week 2, Week 4, Month 3, Month 6, Month 12, Month 18, Month 24, annually up to year 5.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of cytokines in serum</measure>
    <time_frame>At enrollment, prior to axicabtagene ciloleucel infusion on Day 0, Day 3, Day 7, Week 2, Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants experiencing anti-axicabtagene ciloleucel antibodies</measure>
    <time_frame>At enrollment, Week 4, Month 3, every 3 months up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing clinically significant changes in lab values</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Follicular Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Indolent Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>axicabtagene ciloleucel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>axicabtagene ciloleucel</intervention_name>
    <description>A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.</description>
    <arm_group_label>axicabtagene ciloleucel</arm_group_label>
    <other_name>Yescarta®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>axicabtagene ciloleucel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>axicabtagene ciloleucel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Individual has [follicular lymphoma or marginal zone lymphoma that has progressed
             after at least 2 lines of treatment with combination chemoimmunotherapy] (e.g.
             R-bendamustine, R-CHOP).

          2. Individual has [measurable disease].

          3. Individual has no known presence or history of central nervous system (CNS)
             involvement by lymphoma.

          4. If individual is on conventional systemic therapy or systemic inhibitory/stimulatory
             immune checkpoint therapy, individual is able to stop conventional therapy 2 weeks or
             5 half-lives, whichever is shorter, or immune checkpoint therapy 3 half-lives prior to
             planned leukapheresis.

          5. Individual has Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and
             adequate renal, hepatic, pulmonary, and cardiac function

          6. Individual is not pregnant or breastfeeding (female individuals only) and is willing
             to use birth control from the time of consent through 6 months following chimeric
             antigen receptor (CAR) T cell infusion (both male and female individuals).

        Key Exclusion Criteria:

          1. Transformed follicular lymphoma (FL) or marginal zone lymphoma (MZL)

          2. Small lymphocytic lymphoma

          3. Histological Grade 3b FL

          4. Individual will have undergone autologous transplant within 6 weeks of planned
             leukapheresis or has undergone allogeneic transplant.

          5. Individual has evidence of involvement of the heart by lymphoma or requirement for
             urgent therapy due to ongoing or impending oncologic emergency (e.g. mass effect,
             tumor lysis syndrome, etc.)

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kite Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Kite, A Gilead Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>1-844-454-5483(1-844-454-KITE)</phone>
    <email>medinfo@kitepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Winkle</last_name>
      <phone>480-256-3421</phone>
      <email>andrea.winkle@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Javier Munoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Kelly, MD</last_name>
      <phone>323-865-3828</phone>
      <email>kevin.kelly@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Kelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven de Vos, MD, PhD</last_name>
      <phone>310-267-2756</phone>
      <email>devos@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Sven de Vos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pashna Munshi, MD</last_name>
      <phone>202-444-1212</phone>
      <email>pashna.n.munshi@gunet.georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Pashna Munshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinics</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Luis</last_name>
      <phone>305-243-7648</phone>
      <email>nluis@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Rosenblatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Scott</last_name>
      <phone>813-745-7227</phone>
      <email>matthew.scott@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Julio Chavez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystle Benedict</last_name>
      <phone>617-582-8713</phone>
      <email>Krystle_Benedict@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Caron Jacobson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center - John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Yannotti</last_name>
      <phone>551-996-5168</phone>
      <email>kara.yannotti@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Lori Leslie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Gould</last_name>
      <phone>212-342-3849</phone>
      <email>jg3686@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ran Reshef, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center (URMC)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Enfield</last_name>
      <phone>585-276-4404</phone>
      <email>erin_enfield@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Carla Casulo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Szuminski</last_name>
      <phone>614-688-9796</phone>
      <email>nicole.szuminski@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Basem William, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Giraud</last_name>
      <email>Elisabeth.Giraud@fccc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura McIntyre</last_name>
      <email>Laura.McIntyre@fccc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Henry Fung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Fukas</last_name>
      <phone>412-623-6037</phone>
      <email>fukaslj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Alison Sehgal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delia Darst</last_name>
      <phone>615-343-7190</phone>
      <email>delia.h.darst@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Olalekan Oluwole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliana Vallejo</last_name>
      <phone>713-563-4167</phone>
      <email>lnvallejo@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Sherry Adkins</last_name>
      <phone>713-745-3035</phone>
      <email>sadkins@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sattva Neelapu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Immunotherapy Trials Intake</last_name>
      <phone>206-606-4668</phone>
      <email>immunotherapy@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>David Maloney, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Pierre Benite</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 3, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

